Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
3.500
+0.780 (28.68%)
Apr 13, 2026, 12:18 PM EDT - Market open
Allogene Therapeutics Employees
As of December 31, 2025, Allogene Therapeutics had 152 total employees, including 150 full-time and 2 part-time employees. The number of employees decreased by 77 or -33.62% compared to the previous year.
Employees
152
Change (1Y)
-77
Growth (1Y)
-33.62%
Revenue / Employee
n/a
Profits / Employee
-$1,255,829
Market Cap
853.22M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 152 | -77 | -33.62% | 150 | 2 |
| Dec 31, 2024 | 229 | -4 | -1.72% | 226 | 3 |
| Dec 31, 2023 | 233 | -128 | -35.46% | 232 | 1 |
| Dec 31, 2022 | 361 | 51 | 16.45% | 359 | 2 |
| Sep 30, 2022 | 356 | 55 | 18.27% | 356 | 0 |
| Jun 30, 2022 | 344 | 59 | 20.70% | 344 | 0 |
| Mar 31, 2022 | 334 | 58 | 21.01% | 334 | 0 |
| Dec 31, 2021 | 310 | 45 | 16.98% | 308 | 2 |
| Sep 30, 2021 | 301 | 37 | 14.02% | 301 | 0 |
| Jun 30, 2021 | 285 | 49 | 20.76% | 285 | 0 |
| Mar 31, 2021 | 276 | 61 | 28.37% | 276 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Arvinas | 246 |
| Prime Medicine | 146 |
| Alpha Tau Medical | 121 |
| BridgeBio Oncology Therapeutics | 92 |
| Alto Neuroscience | 68 |
| Crescent Biopharma | 44 |
| Forte Biosciences | 19 |
ALLO News
- 4 hours ago - Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma - Business Wire
- 4 hours ago - Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL - GlobeNewsWire
- 2 days ago - Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update - GlobeNewsWire
- 6 weeks ago - Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update - GlobeNewsWire
- 2 months ago - Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T - GlobeNewsWire
- 4 months ago - Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewsWire